Syros Pharmaceuticals (SYRS) Stock Overview
A biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
SYRS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Syros Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$0.30 |
| 52 Week Low | US$0.0001 |
| Beta | 1.08 |
| 1 Month Change | -75.00% |
| 3 Month Change | -50.00% |
| 1 Year Change | -99.90% |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| SYRS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -42.9% | 3.6% | -0.4% |
| 1Y | -99.9% | 26.9% | 12.7% |
Return vs Industry: SYRS underperformed the US Biotechs industry which returned 26.8% over the past year.
Return vs Market: SYRS underperformed the US Market which returned 12.7% over the past year.
Price Volatility
| SYRS volatility | |
|---|---|
| SYRS Average Weekly Movement | 187.9% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SYRS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SYRS's weekly volatility has decreased from 838% to 188% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | n/a | www.syros.com |
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.
Syros Pharmaceuticals, Inc. Fundamentals Summary
| SYRS fundamental statistics | |
|---|---|
| Market cap | US$5.37k |
| Earnings (TTM) | -US$97.81m |
| Revenue (TTM) | US$386.00k |
Is SYRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYRS income statement (TTM) | |
|---|---|
| Revenue | US$386.00k |
| Cost of Revenue | US$88.64m |
| Gross Profit | -US$88.25m |
| Other Expenses | US$9.56m |
| Earnings | -US$97.81m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.65 |
| Gross Margin | -22,862.95% |
| Net Profit Margin | -25,340.67% |
| Debt/Equity Ratio | -369.3% |
How did SYRS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/25 02:09 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syros Pharmaceuticals, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Breidenbach | Oppenheimer & Co. Inc. |
| Zegbeh Jallah | Roth Capital Partners |
| Philip Nadeau | TD Cowen |